

Targeted Oncology Therapeutics Hematology Cancers

Therapeutics, Markets, Products,
Strategies and Forecasts

Report Brochure




Greystone
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Targeted Oncology Therapeutics Hematology Cancers** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, and healthcare marketers with a detailed understanding of the economics, technologies, indications, and commercial opportunities for oncology drugs that target hematology cancers, a classification that includes Leukemias, Lymphomas and Myelomas. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Targeted Oncology Therapies

There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes. More than three dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological, and emotional burden of cancer. This report examines two-dozen leading mAb and kinase inhibitor therapeutic drugs and the biomarkers they utilize.



Executive Summary

Targeted Oncology Therapeutics

Hematology Cancers

Executive Summary

The Recombinant Drug Ecosystem

mAbs and Targeted Oncology Therapeutics

Leukemias

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Childhood Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Myelogenous Leukemia

Lymphomas

Hodgkin Lymphoma

Non-Hodgkin's Lymphoma

Multiple Myeloma

Biological Drugs for Hematology Cancers

Monoclonal Antibodies (Twelve Therapeutic Products)

Tyrosine Kinase Inhibitors

ALL with Philadelphia chromosome (Ph+ ALL)

FDA Approved TKIs (Six Therapeutic Products)

Chimeric Antigen Receptor-T (CAR-T) (Five Products)

The Therapeutic Market Landscape

Diagnostic Tools

Drugs in Development – The Clinical Trial Picture

Leukemias


Lymphomas

Myeloma



FDA-Approved Targeted Oncology

Therapeutics for Hematology Cancers

Numerous Charts, Tables & Visualizations





AMGEN Oncology mAb Product Revenue



Amgen - Approved Oncology Biologicals by Indication

| DrugName | Breast Cancers | Cervical Cancer | Colorectal Cancers | Hematology Cancers | Lung Cancers | Metastatic Gastrointestinal Cancer | Neurological Cancers | Renal Cell Carcinomas |
|----------|----------------|-----------------|--------------------|--------------------|--------------|------------------------------------|----------------------|-----------------------|
| BLINCYTO | | | | | | | | |
| KANJINTI | | | | | | | | |
| MVASI | | | | | | | | |
| VECTIBIX | | | | | | | | |




Clear & Concise Market Segment Data


Oncology mAbs, Competitive Considerations – FDA/EMA Approved Product Market Coverage by Supplier

(Commercial availability may vary due to launch delays related to patent litigation)

| Supplier (group) | Breast Cancers | Cervical Cancer | Colorectal Cancers | Gastric Cancer | Granulomatosis | Hematology Cancers | Lung Cancers | Melanomas | Metastatic Gastric Cancer | Mycosis Fungoidis | Neurological Cancers | Renal Cell Carcinomas | Reproductive Cancer | Rheumatoid Arthritis | SCC of the Head and Neck | Skin Cancers | Soft Tissue Sarcoma | Urothelial Cancers |
|-------------------------|----------------|-----------------|--------------------|----------------|----------------|--------------------|--------------|-----------|---------------------------|-------------------|----------------------|-----------------------|---------------------|----------------------|--------------------------|--------------|---------------------|--------------------|
| AMGEN | ● | ● | ● | | | ● | ● | | ● | | ● | ● | | | | | | |
| ASTELLAS | | | | | | | | | | | | | | | | | | ● |
| ASTRAZENECA | | | | | | ● | ● | | | | | | | | | | | ● |
| BRISTOL MYERS SQUIBB | | | ● | | | ● | ● | ● | | | | ● | | | | | | |
| CELLTRION INC | ● | | | | | ● | | | | | | | | | | | | |
| DAIICHI SANKYO | ● | | | | | | | | | | | | | | | | | |
| ELI LILLY AND CO | | | ● | ● | | | ● | | | | | | | | | | ● | |
| EMD SERONO INC | | | | | | | | | | | | ● | | | | ● | | ● |
| GENENTECH | ● | ● | ● | | ● | ● | ● | | ● | | ● | ● | ● | ● | | | | ● |
| GENZYME | | | | | | | | | | | | | | | | | | |
| GLAXO GRP LTD | | | | | | | | | | | | | | | | | | |
| IMCLONE | | | ● | | | | | | | | | | | | | | | |
| JANSEN BIOTECH | | | | | | | | | | | | | | | | | | |
| KYOWA KIRIN | | | | | | | | | | | | | | | | | | |
| MERCK SHARP DOHME | | | | | | | | | | | | | | | | | | |
| MYLAN GMBH | ● | | | | | | | | | | | | | | | | | |
| PFIZER INC | ● | ● | ● | | | | | | | | | | | | | | | |
| REGENERON PHARMACEUT... | | | | | | | | | | | | | | | | | | |
| SAMSUNG BIOEPI S CO LTD | ● | | | | | | | | | | | | | | | | | |
| SPECTRUM PHARMS | | | | | | | | | | | | | | | | | | |
| UNITED THERAP | | | | | | | | | | | | | | | | | | |
| WYETH PHARMS INC | | | | | | | | | | | | | | | | | | |



SupplierActivityMap



What You Will Learn

- What is the market share of approved hematology cancer therapeutics?
- What is the global supply picture for targeted hematology cancer therapeutics?
- Who are the market leaders, by Indication? by Product?
- What is the therapeutic coverage across all oncology indications? What are the product opportunities?
- What are the established products in this space? by target, indication, API class, revenue?
- What is the competitive picture for the hematology cancer market segments?
- Drug treatment resources
- Competitive therapy map
- Clinical trial activity
- Who are the leading competitors in the field of next-generation hematology cancer therapeutics?

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-440-5710, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched, and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
 300 Franklin Street
 Manchester, NH 03103
 (Call for Account Information)

Mailing Address: Greystone Research Associates
 Client Services
 P.O. Box 1362
 Amherst, NH 03031

Targeted Oncology Therapeutics: Hematology Cancers

Therapeutics, Markets, Products, Strategies & Forecasts

| Select | Format | License | Price (U.S. Funds) | Total |
|-----------------------------------|--------|---------------------|--------------------|-------|
| <input type="checkbox"/> | PDF | Single User License | \$6,850.00 | |
| <input type="checkbox"/> | PDF | Site License | \$9,500.00 | |
| <input type="checkbox"/> | PDF | Corporate License | \$12,500.00 | |
| Total Payment (U.S. funds) | | | | |

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

| Billing Information | Shipping Information |
|----------------------|---|
| Name: | <input type="checkbox"/> Click here if same as Billing Information Name: |
| Title: | Title: |
| Company: | Company: |
| Street Address: | Street Address: |
| City,State/Province: | City,State/Province: |
| Country/Postal Code: | Country/Postal Code: |
| Phone: | Phone: |
| Fax: | Fax: |
| Email: | Email: |